Department of Medical Oncology, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey.
Department of Translational Oncology, Dokuz Eylül University, Institute of Oncology, İzmir, Turkey.
Turk J Gastroenterol. 2023 May;34(5):568-575. doi: 10.5152/tjg.2023.22124.
Hepatocyte growth factor is a cytokine secreted by the stromal cells in the tumor microenvironment. There is little information about the clinical significance of serum hepatocyte growth factor level in patients diagnosed with pancreatobiliary cancer. The objective of the current study was to investigate the relationship between serum hepatocyte growth factor level with inflammation markers and the clinical features of patients with pancreatobiliary cancer.
A total of 62 patients with pancreatobiliary cancer were included in this study. Serum hepatocyte growth factor concentrations were evaluated utilizing the enzyme-linked immunosorbent assay method.
The median serum hepatocyte growth factor level was 329.1 ng/mL (1.4-1051.1). The patients were categorized into 2 groups as those below the median hepatocyte growth factor level (low hepatocyte growth factor) and those above the median hepatocyte growth factor level (high hepatocyte growth factor). While 40.9% of the patients without metastasis were observed to be in the high hepatocyte growth factor group, 72.2% of the metastatic patients were observed to be in the high hepatocyte growth factor group (P = .025). The median levels of monocyte, monocyte-to-lymphocyte ratio, C-reactive protein, and C-reactive protein-to-albumin ratio were found to be significantly higher in the high hepatocyte growth factor group as compared to the low hepatocyte growth factor group (P < .050).
The significant relationship between serum hepatocyte growth factor level and systemic inflammation markers in patients with pancreatobiliary cancer is shown for the first time in our study. This study, which showed a significant relationship between the presence of metastasis and serum hepatocyte growth factor level, suggests that serum hepatocyte growth factor level may be a prognostic biomarker in patients who are diagnosed with pancreatobiliary cancer.
肝细胞生长因子是肿瘤微环境中基质细胞分泌的细胞因子。目前关于诊断为肝胆管癌患者血清肝细胞生长因子水平的临床意义的信息较少。本研究旨在探讨血清肝细胞生长因子水平与炎症标志物及肝胆管癌患者临床特征的关系。
本研究共纳入 62 例肝胆管癌患者。采用酶联免疫吸附试验法检测血清肝细胞生长因子浓度。
中位血清肝细胞生长因子水平为 329.1ng/mL（1.4-1051.1）。将患者分为中位肝细胞生长因子水平以下（低肝细胞生长因子）和中位肝细胞生长因子水平以上（高肝细胞生长因子）两组。无转移患者中 40.9%为高肝细胞生长因子组，转移患者中 72.2%为高肝细胞生长因子组（P=0.025）。高肝细胞生长因子组的单核细胞、单核细胞与淋巴细胞比值、C 反应蛋白和 C 反应蛋白与白蛋白比值中位水平明显高于低肝细胞生长因子组（P＜0.050）。
本研究首次显示，肝胆管癌患者血清肝细胞生长因子水平与全身炎症标志物之间存在显著相关性。本研究显示转移与血清肝细胞生长因子水平之间存在显著关系，表明血清肝细胞生长因子水平可能是诊断为肝胆管癌患者的预后生物标志物。
